USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
The mixed messages on drug pricing policy coming from new US President Donald Trump’s administration are starting to harm healthcare stocks, according to an analyst at the independent broker finnCap. 24 February 2017
Japanese pharma major Daiichi Sankyo has announced a raft of structural changes affecting its corporate activities, research and development (R&D) and biologics-related functions. 24 February 2017
Belgian drug developer Ablynx has announced its 2016 financial results, which show the company received just over 85 million euros ($90 million) in grants, a 10% increase on the year before. 23 February 2017
A fourth-quarter dip in income hit the 2016 financial results of Germany’s Bayer, which have shown just how crucial the strong performance of pharma is to the group's revenue and profit, in particular its anticoagulant Xarelto. 22 February 2017
AusBiotech, the trade federation that represents the Australian biotechnology industry, is to hold a series of investment events in Asian financial hubs next month. 20 February 2017
Despite an initial blip, shares in AstraZeneca have climbed by 8% since the Anglo-Swedish pharma major announced its 2016 results last week, reaching £46.18 ($57.48) by Friday lunchtime. 10 February 2017
Italian drugmaker Recordati has not only announced an increase in revenue for 2016 of more than 10%, but has also predicted that it will rise by a further 26% by 2019. 9 February 2017
GlaxoSmithKline has delivered 2016 sales growth of 6% and improved cash flow in figures boosted by the Brexit-hit pound, but the UK pharma major accepts that generic competition to a big-selling respiratory drug could hit its revenue in 2017. 8 February 2017
The upbeat mood at Danish CNS specialist Lundbeck over its impressive 2016 financial results will be countered by the market reaction to news of its failure in an Alzheimer’s program. 8 February 2017
US biopharma Cytokinetics has agreed to sell a portion of the potential royalty due from US biotech Amgen on worldwide sales of an investigatory heart failure drug to private equity firm Royalty Pharma. 2 February 2017
Merck & Co’s 2016 financial results offer further evidence of why the company is the envy of the industry due to its ownership of the immuno-oncology drug Keytruda (pembrolizumab). 2 February 2017
Shares in AstraZeneca fell around 1.5% this morning as the company provided cautious 2017 guidance as part of its full year and fourth quarter financial results statement. 2 February 2017
US pharma giant Pfizer missed analysts’ estimates with its forecast for revenue for 2017 as it presented a set of results which showed the increasing impact of competition and the company’s focus on mergers and acquisitions (M&A). 31 January 2017
Mindful that the next two years will be massively important for the company and how closely pharma will be watching its progress, it is not surprising that Realm Therapeutics has been keen to let the world know its plans for 2017. 31 January 2017
US pharma major Bristol-Myers Squibb might have been able to point to a 17% increase in its 2016 sales compared to 2015, but it share price and outlook for 2017 tell a different story of the year it has had. 26 January 2017
Beximco Pharmaceuticals has entered into a collaboration with Malaysia’s BioCare Manufacturing, in what will be the Bangladeshi generics firm’s first overseas manufacturing deal. 25 January 2017
Slowing growth in pharmaceuticals has been blamed for a drop in the share price of Johnson & Johnson (NYSE: JNJ) after the world’s biggest healthcare business published its fourth quarter and full 2016 financial results. 24 January 2017
In an expert view piece, Dr Oded Ben-Joseph and Dr Shawn Manning, from investment bank Outcome Capital, advise on how life sciences companies can curtail risk by allocating time and money in a capital-efficient manner. 19 January 2017
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news